Erasca (ERAS) vs Ionis Pharmaceuticals (IONS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Erasca (ERAS) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 366.1% versus a loss of 65.1%. Over five years, IONS leads with a -8.5% price change compared with -11.3% for ERAS. Erasca is the larger company by market cap ($4.78 billion vs $4.43 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | IONS |
|---|---|---|
| Share price | $13.61 | $26.58 |
| Market cap | $4.78B | $4.43B |
| 1-day change | -4.29% | -2.35% |
| YTD return | +265.86% | -66.40% |
| 1-year return | +366.10% | -65.07% |
| 5-year return | -11.28% | -8.50% |
| EPS (TTM) | $-0.97 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $943.71M |
| Revenue growth (YoY) | — | +33.83% |
| Net income (latest FY) | $-124.55M | $-381.39M |
| Gross margin | — | 98.31% |
| Operating margin | — | -40.45% |
| Net margin | — | -40.41% |
| 52-week high | $24.28 | $86.74 |
| 52-week low | $2.81 | $26.53 |
| Distance from 52-week high | -43.95% | -69.36% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +77.15% | +155.19% |
| Average volume | 5.27M | 3.91M |
| Shares outstanding | 350.96M | 166.55M |
| Employees | 103 | 1,485 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed IONS by 431.2 percentage points over the past year.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,485 employees
ERAS vs IONS FAQ
Which is bigger, Erasca or Ionis Pharmaceuticals?
Erasca (ERAS) is larger, with a market capitalization of $4.78B compared with $4.43B for Ionis Pharmaceuticals (IONS).
Which stock has performed better over the past year, ERAS or IONS?
ERAS returned +366.10% over the past 12 months, compared with -65.07% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Erasca and Ionis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.